• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

克罗地亚 COVID-19 疫苗安全监测自发报告系统的准备情况。

The readiness of the spontaneous reporting system for COVID-19 vaccines safety monitoring in Croatia.

机构信息

1Department of Pharmacovigilance and Rational Pharmacotherapy Agency for Medicinal Products and Medical Devices of Croatia 10000 Zagreb, Croatia.

2Centre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry University of Zagreb, 10 000 Zagreb Croatia.

出版信息

Acta Pharm. 2023 Jun 12;73(2):293-310. doi: 10.2478/acph-2023-0029. Print 2023 Jun 1.

DOI:10.2478/acph-2023-0029
PMID:37307371
Abstract

We aimed to identify whether a spontaneous reporting system (SRS) in Croatia could timely identify and confirm signals for COVID-19 vaccines. Post-marketing spontaneous reports of adverse drug reactions (ADRs) following COVID-19 immunisation reported to the Agency for Medicinal Products and Medical Devices of Croatia (HALMED) were extracted and analysed. 6624 cases reporting 30 655 ADRs following COVID-19 immunisation were received from 27 December 2020 to 31st December 2021. Available data in those cases were compared with data available to the EU network at the time when signals were confirmed and minimisation measures were implemented. 5032 cases, reporting 22 524 ADRs, were assessed as non-serious, and 1,592 cases, reporting 8,131 ADRs as serious. The most reported serious ADRs, which were listed in the MedDRA Important medical events terms list, were syncope ( = 58), arrhythmia ( = 48), pulmonary embolism ( = 45), loss of consciousness ( = 43), and deep vein thrombosis ( = 36). The highest reporting rate had Vaxzevria (0.003), followed by Spikevax and Jcovden (0.002), and Comirnaty (0.001). Potential signals were identified, however, they couldn't be timely confirmed solely on cases retrieved by SRS. In order to overcome the limitations of SRS, active surveillance and post-authorisation safety studies of vaccines should be implemented in Croatia.

摘要

我们旨在确定克罗地亚的自发报告系统(SRS)是否能够及时识别和确认 COVID-19 疫苗的信号。从 2020 年 12 月 27 日至 2021 年 12 月 31 日,从克罗地亚药品和医疗器械管理局(HALMED)收到了 6624 例报告 COVID-19 免疫后不良药物反应(ADR)的自发报告,共 30655 例。对这些病例中的可用数据与信号得到确认和采取缓解措施时欧盟网络中可用的数据进行了比较。5032 例,报告 22524 例非严重 ADR,1592 例,报告 8131 例严重 ADR。报告最多的严重 ADR 是晕厥(=58)、心律失常(=48)、肺栓塞(=45)、意识丧失(=43)和深静脉血栓形成(=36),这些都是 MedDRA 重要医学事件术语列表中列出的。Vaxzevria(0.003)的报告率最高,其次是 Spikevax 和 Jcovden(0.002),以及 Comirnaty(0.001)。虽然识别到了潜在信号,但仅凭 SRS 检索到的病例无法及时确认。为了克服 SRS 的局限性,应在克罗地亚实施疫苗主动监测和上市后安全性研究。

相似文献

1
The readiness of the spontaneous reporting system for COVID-19 vaccines safety monitoring in Croatia.克罗地亚 COVID-19 疫苗安全监测自发报告系统的准备情况。
Acta Pharm. 2023 Jun 12;73(2):293-310. doi: 10.2478/acph-2023-0029. Print 2023 Jun 1.
2
Adverse drug reactions of non-opioid and opioid analgesics reported to Croatian national authority from 2007 to 2014.2007年至2014年向克罗地亚国家当局报告的非阿片类和阿片类镇痛药的药物不良反应。
Acta Med Acad. 2017 Nov;46(2):94-104. doi: 10.5644/ama2006-124.194.
3
Analysis of spontaneous reporting of suspected adverse drug reactions for non-analgesic over-the-counter drugs from 2008 to 2017.2008 年至 2017 年非麻醉性非处方药物不良反应自发报告分析。
BMC Pharmacol Toxicol. 2019 Oct 18;20(1):60. doi: 10.1186/s40360-019-0338-2.
4
Adverse drug reactions that arise from the use of medicinal products outside the terms of the marketing authorisation.药品在上市许可规定的条件之外使用而产生的药物不良反应。
Res Social Adm Pharm. 2020 Jul;16(7):928-934. doi: 10.1016/j.sapharm.2019.10.003. Epub 2019 Oct 7.
5
COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.COVID-19 mRNA 疫苗:一项回顾性观察性药物警戒研究。
Clin Drug Investig. 2022 Dec;42(12):1065-1074. doi: 10.1007/s40261-022-01216-9. Epub 2022 Oct 23.
6
COVID-19 Vaccines Adverse Reactions Reported to the Pharmacovigilance Unit of Beira Interior in Portugal.向葡萄牙贝拉内斯省药物警戒部门报告的新冠疫苗不良反应
J Clin Med. 2022 Sep 23;11(19):5591. doi: 10.3390/jcm11195591.
7
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.评估患者向英国“黄卡计划”报告药物不良反应的情况:文献回顾、描述性和定性分析以及问卷调查。
Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200.
8
Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.比较向欧洲药品管理局报告的儿科和成人疑似药物不良反应:对药物警戒学的启示。
Paediatr Drugs. 2014 Aug;16(4):309-19. doi: 10.1007/s40272-014-0076-2.
9
Safety profile of COVID-19 vaccines, preventive strategies, and patient management.新型冠状病毒肺炎疫苗的安全性、预防策略及患者管理
Expert Rev Vaccines. 2022 Aug;21(8):1087-1095. doi: 10.1080/14760584.2022.2078311. Epub 2022 May 19.
10
French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge.法国新冠疫苗药物警戒组织:一大挑战。
Therapie. 2021 Jul-Aug;76(4):297-303. doi: 10.1016/j.therap.2021.05.003. Epub 2021 May 7.